Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab Boye J; Elter T; Engert AAnn Oncol 2003[Apr]; 14 (4): 520-35The chimeric anti-CD20 monoclonal antibody rituximab has become part of the standard therapy for patients with non-Hodgkin's lymphoma (NHL). To date, more than 300 000 patients have been treated with rituximab worldwide, including patients with indolent and aggressive NHL, Hodgkin's disease and other B-cell malignancies. Combination of rituximab with cytotoxic agents or cytokines has been explored in a number of different studies. Rituximab is now also approved for patients with diffuse large B-cell lymphoma when combined with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone). The monoclonal antibody is generally well tolerated. Most adverse events are infusion-associated, including chills, fever and rigor related to the release of cytokines.|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/adverse effects/pharmacology/*therapeutic use[MESH]|Antineoplastic Agents/adverse effects/pharmacology/*therapeutic use[MESH]|Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use[MESH]|Autoimmune Diseases/drug therapy[MESH]|Chills/chemically induced[MESH]|Cyclophosphamide/administration & dosage[MESH]|Doxorubicin/administration & dosage[MESH]|Fever/chemically induced[MESH]|Hodgkin Disease/*drug therapy[MESH]|Humans[MESH]|Lymphoma, Mantle-Cell/*drug therapy[MESH]|Lymphoma, Non-Hodgkin/*drug therapy[MESH]|Lymphoproliferative Disorders/drug therapy/etiology[MESH]|Multiple Myeloma/*drug therapy[MESH]|Prednisone/administration & dosage[MESH]|Rituximab[MESH]|Treatment Outcome[MESH]|Vincristine/administration & dosage[MESH] |